| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Marketing > Office Furniture Manufacturers in Great Britain are Facing More Challenges |
|
Main Subject - Office Furniture Manufacturers in Great Britain are Facing More Challenges
After several years of healthy growth during the second half of the 1990s, the office furniture indu According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product stry in Great Britain has entered a phase of stagnation or only modest growth. Most of the observed ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in growth goes on account of higher prices. Sales in real-terms - that is after the elimination of the lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. impact of inflation - are now approximately thirty percent lower than at the beginning of this centu here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ry. We anticipate that growth this year and again next year will remain lacklustre and hover around d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro the two percent range. If our predictions are correct, the market value will exceed for the first ti ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc me the ?700 million mark this year. Sales of filing cabinets and other office storage furniture far easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi d particularly poorly. This is not surprising and a reflection of the continuing transition from pap nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically er-based offices to paperless offices. On the other hand, workstations and other system furniture, a and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ s well as office chairs have been performing better. In fact the market share of workstations and si ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi milar furniture is now close to one-half, while it was only in the forty percent range during the la ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a te 1990s. An interesting trend is that wooden office furniture is gaining in popularity, even thoug dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod h such products are generally more expensive than metal or plastic furniture. A possible explanation cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin for this phenomenon could be the increasing use of technology in modern offices. Wooden furniture o tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen fers a good counterbalance to an otherwise sterile environment by providing more warmth to the offic t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel e. Foreign competition remains a formidable and growing challenge for UK office furniture manufactu ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust rers. The so called import penetration – that is the percentage of foreign produced office furniture y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products – approaches one-third. We predict that it will exceed 50% by 2010. During the 90s the ratio was l . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ess than one-quarter. Most imported products still have their origin in other European countries, bu elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip t imports from China and other Asian countries (such as Vietnam) show by far the fastest growth rate tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Open For Business? Regular Business Hours Should Be Regular Business Hours Copywriting For Your Scrapbook Business
|